ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Sphera / Blackrock

<< Previous

Bullboard Posts

Next >>

Comment by garygpon Jul 31, 2024 1:57pm

61 Views

Post# 36156609

RE:RE:RE:RE:Sphera / Blackrock

FWIW, Goldtech is very close in his numbers. After last years foolish financing, I did see in a publication that Sphera owned between 11 and 12 percent of issued and outstanding shares in ProMIS.

I don't remember where I saw this, possibly on the TSX website at that time and that was a year ago. I can't begin to imagine what they own now.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant